Title: Chemical stability of 4'-azidocytidine and its prodrug balapiravir.
Journal: Drug development and industrial pharmacy 20100401
Title: Phosphoramidate prodrugs of 2'-C-methylcytidine for therapy of hepatitis C virus infection.
Journal: Journal of medicinal chemistry 20090910
Title: Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C.
Journal: Hepatology (Baltimore, Md.) 20080801
Title: R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin.
Journal: Hepatology (Baltimore, Md.) 20080801
Title: Physicochemical properties of the nucleoside prodrug R1626 leading to high oral bioavailability.
Journal: Drug development and industrial pharmacy 20080701
Title: The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors.
Journal: Antimicrobial agents and chemotherapy 20080501
Title: Future treatment options for HCV: double, triple, what is the optimal combination?
Journal: Best practice & research. Clinical gastroenterology 20080101
Title: Nguyen NM, et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis. 2013 May 1;207(9):1442-1450.
Title: Nelson DR, et al. Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients.Ann Hepatol. 2012 Jan-Feb;11(1):15-31.
Title: Yen-Liang Chen, et al. Activation of Peripheral Blood Mononuclear Cells by Dengue Virus Infection Depotentiates Balapiravir. J Virol. 2014 Feb;88(3):1740-7.
